Table 2.
Cumulative HNSCC MCTS Drug Impact Scores.
| Compound | FaDu | UM-22B | Cal33 | BIRC56 | OSC-19 | Total | Rank |
|---|---|---|---|---|---|---|---|
| 5-FU* | 2.5 | 3.0 | 1.0 | 1.0 | 2.0 | 9.5 | 10 |
| Methotrexate* | 2.0 | 2.0 | 0.5 | 1.0 | 0.5 | 6.0 | 16 |
| Bleomycin* | 1.0 | 3.5 | 1.0 | 0.5 | 1.5 | 7.5 | 13 |
| Docetaxel* | 4.0 | 3.5 | 2.0 | 3.5 | 3.5 | 16.5 | 4 |
| Cisplatin* | 3.5 | 3.5 | 3.0 | 3.0 | 3.0 | 16.0 | 5 |
| Gefitinib | 3.0 | 3.0 | 2.5 | 2.0 | 3.0 | 13.5 | 6 |
| Erlotinib | 1.5 | 2.5 | 1.5 | 0.0 | 1.0 | 6.5 | 15 |
| Dasatinib | 2.5 | 2.5 | 1.5 | 2.0 | 2.0 | 10.5 | 8 |
| Sunitinib | 4.0 | 4.0 | 3.0 | 3.5 | 3.5 | 18.0 | 2 |
| Ruxolitinib | 3.0 | 2.0 | 1.5 | 3.5 | 2.5 | 12.5 | 7 |
| Doxorubicin | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 20.0 | 1 |
| Etoposide | 2.5 | 2.5 | 1.5 | 0.5 | 2.0 | 9.0 | 11 |
| Topotecan | 2.5 | 2.5 | 1.5 | 0.0 | 0.5 | 7.0 | 14 |
| Dactolisib | 1.0 | 2.0 | 1.5 | 2.0 | 0.5 | 7.0 | 14 |
| Buparlisib | 2.5 | 2.5 | 1.5 | 2.0 | 2.0 | 10.5 | 8 |
| Romidepsin | 2.5 | 1.5 | 2.0 | 2.5 | 2.0 | 10.5 | 8 |
| Bortezomib | 2.0 | 2.0 | 1.5 | 1.0 | 2.0 | 8.5 | 12 |
| Everolimus | 4.0 | 3.0 | 3.0 | 3.0 | 4.0 | 17.0 | 3 |
| Ganetespib | 2.5 | 2.0 | 2.0 | 1.5 | 2.0 | 10.0 | 9 |
Cumulative HNSCC MCTS drug impact scores are the sum of GTB GI, live/dead staining, and morphology drug impact scores in Supplemental Tables S3–S5. Maximum drug impact score per HNSCC MCTS culture = 4, and across all cultures = 20. Minimum drug impact score per HNSCC MCTS culture = 0, and across all cultures = 0.
*
Approved for HNSCC therapy.